UNIVERSAL TECHNICAL INSTITUT (UTI) Fundamental Analysis & Valuation
NYSE:UTI • US9139151040
Current stock price
36.29 USD
+0.75 (+2.11%)
Last:
This UTI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. UTI Profitability Analysis
1.1 Basic Checks
- In the past year UTI was profitable.
- In the past year UTI had a positive cash flow from operations.
- UTI had positive earnings in each of the past 5 years.
- UTI had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With a decent Return On Assets value of 6.44%, UTI is doing good in the industry, outperforming 71.23% of the companies in the same industry.
- UTI has a Return On Equity of 15.98%. This is in the better half of the industry: UTI outperforms 75.34% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 8.69%, UTI is in the better half of the industry, outperforming 75.34% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for UTI is significantly below the industry average of 15.52%.
- The last Return On Invested Capital (8.69%) for UTI is above the 3 year average (7.27%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROIC | 8.69% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
1.3 Margins
- UTI has a better Profit Margin (6.28%) than 64.38% of its industry peers.
- In the last couple of years the Profit Margin of UTI has grown nicely.
- UTI has a better Operating Margin (8.38%) than 65.75% of its industry peers.
- In the last couple of years the Operating Margin of UTI has grown nicely.
- The Gross Margin of UTI (49.62%) is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of UTI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% |
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
2. UTI Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so UTI is destroying value.
- The number of shares outstanding for UTI has been increased compared to 1 year ago.
- Compared to 5 years ago, UTI has more shares outstanding
- UTI has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 3.90 indicates that UTI is not in any danger for bankruptcy at the moment.
- UTI has a better Altman-Z score (3.90) than 78.08% of its industry peers.
- The Debt to FCF ratio of UTI is 6.28, which is on the high side as it means it would take UTI, 6.28 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of UTI (6.28) is better than 69.86% of its industry peers.
- A Debt/Equity ratio of 0.29 indicates that UTI is not too dependend on debt financing.
- UTI has a Debt to Equity ratio of 0.29. This is comparable to the rest of the industry: UTI outperforms 56.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Altman-Z | 3.9 |
ROIC/WACC0.99
WACC8.74%
2.3 Liquidity
- UTI has a Current Ratio of 1.14. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
- With a Current ratio value of 1.14, UTI perfoms like the industry average, outperforming 43.84% of the companies in the same industry.
- UTI has a Quick Ratio of 1.14. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
- UTI's Quick ratio of 1.14 is in line compared to the rest of the industry. UTI outperforms 46.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 |
3. UTI Growth Analysis
3.1 Past
- UTI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
- The Earnings Per Share has been growing by 65.96% on average over the past years. This is a very strong growth
- Looking at the last year, UTI shows a quite strong growth in Revenue. The Revenue has grown by 12.59% in the last year.
- The Revenue has been growing by 22.67% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
3.2 Future
- The Earnings Per Share is expected to grow by 5.89% on average over the next years.
- The Revenue is expected to grow by 8.84% on average over the next years. This is quite good.
EPS Next Y-31.19%
EPS Next 2Y-10.6%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. UTI Valuation Analysis
4.1 Price/Earnings Ratio
- UTI is valuated quite expensively with a Price/Earnings ratio of 37.41.
- The rest of the industry has a similar Price/Earnings ratio as UTI.
- UTI's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.91.
- The Price/Forward Earnings ratio is 39.83, which means the current valuation is very expensive for UTI.
- The rest of the industry has a similar Price/Forward Earnings ratio as UTI.
- UTI is valuated expensively when we compare the Price/Forward Earnings ratio to 21.99, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.41 | ||
| Fwd PE | 39.83 |
4.2 Price Multiples
- UTI's Enterprise Value to EBITDA ratio is in line with the industry average.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of UTI is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 123.72 | ||
| EV/EBITDA | 17.29 |
4.3 Compensation for Growth
- The decent profitability rating of UTI may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.57
EPS Next 2Y-10.6%
EPS Next 3Y5.89%
5. UTI Dividend Analysis
5.1 Amount
- No dividends for UTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
UTI Fundamentals: All Metrics, Ratios and Statistics
NYSE:UTI (4/29/2026, 3:37:16 PM)
36.29
+0.75 (+2.11%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Industry Strength12.42
Industry Growth64.6
Earnings (Last)02-04 2026-02-04/amc
Earnings (Next)05-06 2026-05-06
Inst Owners96.88%
Inst Owner Change3.67%
Ins Owners2.49%
Ins Owner Change3.2%
Market Cap2.00B
Revenue(TTM)855.03M
Net Income(TTM)53.69M
Analysts81.82
Price Target38.42 (5.87%)
Short Float %5.45%
Short Ratio4.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.57%
Min EPS beat(2)28.91%
Max EPS beat(2)66.22%
EPS beat(4)4
Avg EPS beat(4)59.42%
Min EPS beat(4)28.91%
Max EPS beat(4)73.27%
EPS beat(8)7
Avg EPS beat(8)48.68%
EPS beat(12)11
Avg EPS beat(12)85.96%
EPS beat(16)14
Avg EPS beat(16)183.11%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.47%
Max Revenue beat(2)0.82%
Revenue beat(4)4
Avg Revenue beat(4)1.74%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.01%
Revenue beat(12)12
Avg Revenue beat(12)2.35%
Revenue beat(16)15
Avg Revenue beat(16)2.9%
PT rev (1m)0%
PT rev (3m)0.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-103.86%
EPS NY rev (1m)0%
EPS NY rev (3m)0.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.41 | ||
| Fwd PE | 39.83 | ||
| P/S | 2.34 | ||
| P/FCF | 123.72 | ||
| P/OCF | 25.78 | ||
| P/B | 5.94 | ||
| P/tB | 6.97 | ||
| EV/EBITDA | 17.29 |
EPS(TTM)0.97
EY2.67%
EPS(NY)0.91
Fwd EY2.51%
FCF(TTM)0.29
FCFY0.81%
OCF(TTM)1.41
OCFY3.88%
SpS15.54
BVpS6.11
TBVpS5.21
PEG (NY)N/A
PEG (5Y)0.57
Graham Number11.5432 (-68.19%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROCE | 11.63% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.82% | ||
| ROICexgc | 13.27% | ||
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% | ||
| FCFM | 1.89% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score7
Asset Turnover1.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Debt/EBITDA | 0.93 | ||
| Cap/Depr | 181.06% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 13.88 | ||
| Cash Conversion | 73.39% | ||
| Profit Quality | 30.06% | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 3.9 |
F-Score7
WACC8.74%
ROIC/WACC0.99
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
EPS Next Y-31.19%
EPS Next 2Y-10.6%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
EBIT growth 1Y-0.64%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.18%
EBIT Next 3Y27.41%
EBIT Next 5YN/A
FCF growth 1Y371.76%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y35.47%
OCF growth 3Y28.35%
OCF growth 5Y54.57%
UNIVERSAL TECHNICAL INSTITUT / UTI Fundamental Analysis FAQ
What is the fundamental rating for UTI stock?
ChartMill assigns a fundamental rating of 5 / 10 to UTI.
What is the valuation status for UTI stock?
ChartMill assigns a valuation rating of 2 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.
What is the profitability of UTI stock?
UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.
What is the valuation of UNIVERSAL TECHNICAL INSTITUT based on its PE and PB ratios?
The Price/Earnings (PE) ratio for UNIVERSAL TECHNICAL INSTITUT (UTI) is 37.41 and the Price/Book (PB) ratio is 5.94.
Can you provide the expected EPS growth for UTI stock?
The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.19% in the next year.